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Objective: Mitotane induces hepatic CYP3A4 activity, resulting in accelerated 
cortisol inactivation, and also increases cortisol binding globulin (CBG). Therefore, 
higher hydrocortisone doses are required in patients with adrenocortical cancer 
(ACC) on mitotane treatment. Modified release hydrocortisone has not been used in 
mitotane-treated ACC patients yet. 
Aim: Case series to compare serum cortisol, calculated free serum cortisol and 
ACTH levels in ACC patients on mitotane treatment with immediate and modified 
release hydrocortisone. 
Design: Pharmacokinetics of immediate and modified release hydrocortisone, each 
administered at a dose of 40-20-0mg, in 9 patients with ACC and adjuvant mitotane 
treatment. For comparison, ten patients with secondary adrenal insufficiency (SAI) on 
three different hydrocortisone regimens, and ten healthy males were included. 
Methods: Serum cortisol and plasma ACTH were measured by chemiluminescent 
enzyme immunoassay, and CBG by RIA, followed by calculation of free cortisol. 
Results: Calculated free serum cortisol levels after 40mg immediate release 
hydrocortisone in ACC patients (46±14nmol/l) were similar to those after 10mg 
immediate release hydrocortisone intake in men with SAI (64±16nmol/l) or to the 
physiological morning free cortisol levels in healthy subjects (31±5nmol/l), Compared 
to immediate release hydrocortisone, free cortisol levels after 40mg modified release 
hydrocortisone in ACC patients were significantly lower (12±3nmol/l; p=0.03) 
resulting in a generally lower AUC (98±21 vs 149±37 nmol*h/l; p=0.02).  
Conclusions: 40-20-0mg immediate release, but not modified release 
hydrocortisone, resulted in sufficient glucocorticoid coverage in patients with ACC 
under mitotane treatment. The use of equivalent doses of modified release 
hydrocortisone preparation should be avoided in patients on mitotane treatment. 
 
Introduction 
Adrenocortical cancer (ACC) is a rare malignancy that occurs in approximately 0.5-2 
per million persons per year 1;2. The only curative treatment is radical surgery 3. 
However, even after initial curative surgery, 80% of the patients develop recurrent 
disease within two years 4. Adrenolytic therapy with mitotane (o’p’-DDD) is the 
established adjuvant therapy for ACC patients after R0 resection 5 and also the 
primary treatment for patients with advanced ACC (3), either as monotherapy or in 
combination with cytotoxic chemotherapy. Mitotane has been shown to extend 
disease-free survival in retrospective analyses 6;7. Recent data shows that mitotane 
confers adrenolytic activity and down-regulation of steroidogenesis by lipid-induced 
ER-stress through inhibition of the activity of SOAT-1 8. As mitotane affects all 
adrenocortical steroid production it is necessary to replace glucocorticoids and 
sometimes mineralocorticoids in treated patients. However, mitotane is a strong 
inducer of hepatic cytochrome CYP3A4 activity 9;10, which inactivates cortisol to 6β-
hydroxycortisol. Mitotane also increases cortisol binding globulin (CBG) 11. These 
effects result in both a significantly increased cortisol metabolism and reduced free, 
active cortisol 12-16. Therefore, classic hydrocortisone replacement doses of  20 
mg/day, as used in adrenal insufficiency, are not sufficient in ACC patients on 
mitotane and higher dosages (40-80mg/day) are necessary.  
A modified-release hydrocortisone preparation (Plenadren©, formerly known as 
Duocort®), 17;18, is available across Europe for replacement therapy in adult patients 
with adrenal insufficiency. It is administered in the morning and contains a rapid-
release part and a delayed released part of hydrocortisone suggesting that only a 
once daily dose of hydrocortisone might be necessary. Improvement in QoL, blood 
pressure and metabolic parameters was demonstrated in 64 patients with Addison’s 
disease 19. In an open, prospective trial in Addison patients modified-release 
hydrocortisone decreased BMI and HbA1c compared with immediate release HC 
treatment 20.  
Patients with ACC on mitotane treatment often suffer from significant impairment by 
the disease and associated treatment. The number of tablets that need to be 
ingested is mostly high, making it desirable to reduce their amount. The rapid 
metabolic inactivation of cortisol during mitotane treatment may not only increase the 
dose of hydrocortisone needed to be taken but also necessitate shortening the time 
intervals between the doses. Thus, a modified-release hydrocortisone might be a 
useful alternative in this patient group. However, although authorized for the use in 
patients with ACC, it is unclear how concurrent mitotane treatment influences the 
pharmacokinetic profile of modified-release hydrocortisone. Besides increased 
metabolic inactivation by CYP3A4 induction, gastrointestinal side effects that can be 
associated with mitotane treatment may represent a further safety issue in this 
patient group. Of note, even for immediate release hydrocortisone, detailed data 
regarding serum pharmacokinetics in mitotane treated ACC patients is not available.  
In a series of ACC patients in whom modified release hydrocortisone was considered 
as alternative treatment to immediate release hydrocortisone, we carried out 24-h 
pharmacokinetic measurements comparing cortisol (serum and saliva), free serum 
cortisol and plasma ACTH levels during one day of immediate release hydrocortisone 
and modified-release hydrocortisone, respectively, both administered at a dose of 40 




Nine adult patients with histologically confirmed ACC on stable mitotane treatment for 
at least 4 months in whom alternative replacement therapy with modified release 
hydrocortisone was considered, were investigated. ENS@T stage at diagnosis was 2 
(n=8) and 3 (n=1). The reason for mitotane treatment was adjuvant therapy (n=5) or 
metastatic disease (n=4; abdominal lymph nodes and lung) treatment. All patients 
had an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 and 
no signs of severe renal or hepatic insufficiency. None of the patients had other 
concomitant anticancer treatment except from mitotane. However, two patients had 
received streptozotocin chemotherapy at an earlier stage. Immediate release 
hydrocortisone replacement therapy was taken for at least 4 months prior to the 
pharmacokinetic assessment. No patient received supplementary mineralocorticoid 
treatment. No patient experienced signs of hypocortisolism at time of investigation. 
Six patients had mitotane plasma levels within the proposed therapeutic range (14-
20mg/l), three patients had levels below this range (6.6-9.6mg/l). Immediate release 
and modified release hydrocortisone are freely available for treatment of patients with 
adrenal insufficiency in Germany. All patients provided written informed consent for 
additional evaluation of blood, saliva and urine samples. 
Design and assessments 
On study day 1, ACC patients on mitotane treatment were taking 60mg conventional 
hydrocortisone (40-20-0mg), during study day 2 they took the same dose of modified-
release hydrocortisone (40-20-0mg). On both days the timing of hydrocortisone tablet 
intake was 8:00h and 12:00h. Mitotane tablets were taken during meal times at 9:00 
and 13:00. Blood and saliva samples were taken at 7:30, 8:00, 9:00, 10:00, 11:00, 
12:00, 13:00, 14:00, 15:00, 16:00, 17:00. Saliva samples were collected with the 
Salivette system (Sarstedt, Etten-Leur, The Netherlands) in accordance with the 
manufacturer´s instructions. 
24-hour urines were collected for analysis of urinary cortisol metabolites two weeks 
prior to the pharmacokinetic measurements while the patients were on 60mg 
conventional hydrocortisone (40-20-0mg).  
Laboratory Measurements 
Serum cortisol was measured by a solid-phase competitive chemiluminescent 
enzyme immunoassay (Siemens Healthcare, Erlangen, Germany), with an analytical 
sensitivity of 5.5 nmol/l (0.2 µg/dl). The intra- and interassay coefficients of variability 
(CVs) of the cortisol assay were 6.9% and 7.3%, respectively. Plasma ACTH was 
measured by a solid-phase, two-site sequential chemiluminescent assay (Siemens 
Healthcare). The intra- and interassay CVs were 9.6% and 8.8%, respectively. 
Salivary cortisol was analysed by electrochemiluminescence immunoassay (ECLIA) 
(Roche Diagnostics, Germany).  
Serum CBG was measured by radioimmunoassay (MyBioSource, San Diego, 
California, USA). The intra- and interassay coefficients of variability (CVs) of the CBG 
RIA assay 3.9% and 5.5%, respectively. Calculated free cortisol was derived using 
the Coolens’ equation: U2 × K (1 + N) + U × [1 + N + K(T − C)] − C = 0, where C is 
total cortisol (µM), T is CBG (µM), U is unbound cortisol, and K is the affinity of CBG 
for cortisol at 37oC 21. N is the ratio of albumin bound to free cortisol, and 1.74 is the 
value used. For K a value of 3x10-7 M-1 was assumed. This results in the formula 
U=(Z2 + 0.0122*C)½ – Z(µM) with Z=0.0167+0.182(T-C). We did not use the free 
cortisol index (calculated free unbound cortisol) as published by others 22. 
Urine steroid metabolite excretion analysis was carried out by gas 
chromatography/mass spectrometry as previously described 23. 
Mitotane levels at baseline were measured as previous described, by using a gas 
chromatography-electron capture detection assay 24. 
Control cohort 
For comparison with hydrocortisone pharmacokinetics in non mitotane-treated 
patients we included data from a recently published prospective study 25 investigating 
ten adult male patients with secondary adrenal deficiency on three different 
hydrocortisone regimens (20mg 8:00 + 10mg 16:00; 10mg 8:00 + 10mg 16:00; 10mg 
8:00 + 5mg 16:00) and ten healthy male controls. Measurements and analytical 
methods were described previously 25. In addition, 24-h urines were collected in all 
control subjects.  
Statistical analyses 
Area under the curve (AUC) was calculated by using the linear trapezoid method for 
the study time 8:00 until 17:00. Data are shown in mean ± SEM if not stated 
differently. P-values <0.05 were considered statistically significant. Independent 
samples t-test was used for two groups comparison and the Mann-Whitney U test for 
variables which were not normally distributed. Statistical analyses were performed 
using SPSS 15.0 (IBM, Armonk, NY, USA). 
Results 
Nine patients with ACC on mitotane treatment and on a stable daily immediate 
release hydrocortisone dose of 60mg were investigated. The clinical characteristics 
of the patients are shown in Table 1. 
Serum cortisol levels showed a wide variation in the supraphysiological range (1300-
3900nmol/l) after immediate release hydrocortisone intake, and a more homogenous 
pattern, but unanimously much lower profile, after modified release hydrocortisone 
intake (570-1630nmol/l) in ACC patients (Figure 1). After 40mg of immediate release 
hydrocortisone intake the serum cortisol level peaked significantly higher than with 
40mg modified release hydrocortisone (2105±298 vs 1015±120nmol/l; p=0.003). The 
morning peak of immediate release hydrocortisone appeared one hour after the 
tablet intake, whereas the peak after the modified release hydrocortisone appeared 
two hours after tablet intake. The AUC of the serum cortisol levels was significantly 
higher with immediate release hydrocortisone than with modified release 
hydrocortisone (10577±1393 vs 8047±1021nmol*h/l,; p=0.03).  
Most of the ACC patients showed suppressed ACTH levels with no differences 
between the two hydrocortisone preparations (data not shown).  
Urine analysis confirmed the previously described 10 enhanced cortisol metabolism 
with an increased CYP3A4 activity and reduced 5α-reductase activity, and an overall 
increased total glucocorticoid excretion in our ACC patients on mitotane (Table 2).  
Most of the cortisol (80-85%) is bound to the specific binding protein corticosteroid 
binding globulin (CBG), approx. 10% to albumin and the remaining is present in the 
free form. It is assumed that the bioavailability of endogenous glucocorticoids is 
predominantly influenced by CBG, and in situations where CBG levels are altered, 
e.g. mitotane treatment, total cortisol levels may not adequately represent the free 
cortisol fraction. It is assumed that the biologically active level of cortisol to which 
tissues are exposed is free cortisol. Therefore we measured CBG, and showed that 
serum CBG levels in ACC patients were high (median 2.50 µmol/l). By correcting for 
the sex-specific upper-limit of the normal range, the CBG levels were 1.36- (0.87-3.0) 
fold (mean (range)) above sex-specific upper-limit of normal.  
In ACC patients, calculated free cortisol levels showed more pronounced peaks (12-
144nmol/l) after tablet intake of immediate release hydrocortisone (Figure 2a), 
whereas the peaks were blunted after intake of modified release hydrocortisone (5-
33nmol/l) (Figure 2b). This resulted in significant, fourfold higher mean free cortisol 
levels after immediate release than after modified release hydrocortisone intake 
(46±14 vs 12±3nmol/l; p=0.03) (Figure 3a).  
For comparison with immediate release hydrocortisone pharmacokinetics in non 
mitotane-treated patients, we included data from ten adult male with secondary 
adrenal insufficiency and ten healthy controls. In men with secondary adrenal 
insufficiency, a morning dose of immediate release hydrocortisone resulted in a mean 
free cortisol level of 64±16nmol/l (10mg dose) and 128±22nmol/l (20mg dose), 
respectively (Figure 3b). Physiological morning free cortisol levels peaked around 
31±5nmol/l in ten healthy men (Figure 3b). 
The AUC of the calculated free cortisol levels was significantly higher with immediate 
release hydrocortisone than with modified release hydrocortisone (149±37 vs 
98±21nmol/l/h, respectively; p=0.02). Compared to the available data from men with 
secondary adrenal insufficiency, the AUC of the calculated free cortisol levels during 
treatment of immediate release hydrocortisone was slightly higher in ACC patients 
under mitotane than the AUC achieved by a 10mg-10mg-0mg treatment in secondary 
male AI patients but lower than values achieved by a 20mg-10mg-0mg regime. The 
AUC of calculated free cortisol levels with 40-20-0mg modified release 
hydrocortisone (70±11nmol/l) resembled the levels achieved by a 10mg-5mg 
immediate release hydrocortisone regimen in male secondary AI patients 
(114±14nmol).  
Salivary cortisol levels showed large variations after tablet intake and reached very 
high levels in some patients (Figure 4), exceeding normal salivary cortisol morning 
levels (1.3-25.7nmol/l) 20-50-fold. No significant difference in salivary cortisol levels 
was observed between immediate or modified release hydrocortisone intake.  
 
Discussion 
The main finding in our ACC patient group with mitotane treatment is that modified 
release hydrocortisone resulted in much lower total and free cortisol levels than 
immediate release hydrocortisone despite the administration of identical doses. In 
addition, modified release hydrocortisone in ACC patients lacked the physiological 
morning free cortisol peak seen in healthy subjects. In contrast, immediate release 
hydrocortisone in ACC patients provided a similar morning free cortisol peak as seen 
in healthy males and in males with secondary adrenal insufficiency with a 10mg 
immediate release hydrocortisone morning dose 25.    
In a previously published pharmacokinetic study with modified release hydrocortisone 
the time to reach a clinically significant plasma concentration of cortisol (>200 nmol/l) 
was within 20 min and a mean peak of 431 nmol/l was obtained within 50 min after 
administration of the 20 mg tablet 18. A 20mg tablet at a fasted state resulted in an 
AUC of 3634 nmol*h/l in healthy subjects 18. In comparison to that study, here we 
administered the three-fold dose of modified release hydrocortisone in our patients 
and received a mean AUC of 8047 nmol*h/l. The slightly lower than expected rate 
might be explained by the fact that the absorption and bioavailability is not fully dose 
proportional. This is most likely due to reduced dissolution rate kinetics of 
hydrocortisone in the intestinal lumen at the higher dose that will in turn reduce the 
absorption rate 18. In addition, we studied ACC patients on mitotane treatment and 
not healthy volunteers. Mitotane is known to have a wide range of gastrointestinal 
side effects 26 possibly influencing intestinal hydrocortisone absorption. Furthermore 
CYP3A4 induction by mitotane results in rapid inactivation of more than 50% of 
administered hydrocortisone, explaining the need for at least doubling of the 
hydrocortisone replacement dose in mitotane-treated patients to achieve a 
comparable glucocorticoid exposure as is reached in subjects not treated with 
CYP3A4 inducing compounds 10. Comparing mean serum total cortisol AUC of 
immediate and modified release hydrocortisone in ACC patients on mitotane resulted 
in a trend to lower AUC for modified release hydrocortisone (10577±4179 nmol/l*h 
vs. 8047±3066 nmol/l*h, p=0.163), suggesting that glucocorticoid exposure achieved 
by modified release hydrocortisone might be lower compared to immediate release 
hydrocortisone. This difference is similar to what has been observed in patients with 
Addison's disease receiving either glucocorticoid replacement.  
Interestingly, the total levels of cortisol achieved by a treatment with 40-20-0 
immediate release regimen are high (Figure 1), suggesting that daily doses of 40-
50mg of immediate release hydrocortisone might be sufficient. However, this dose 
reduction would not be justified by our observation that free cortisol levels were 
comparable to the levels obtained with a 10mg immediate release morning dose in 
patients with adrenal insufficiency (Figure 2-3) 25. In general, deduced from the 
cortisol levels measured in these patients, glucocorticoid coverage was achieved by 
the 40-20-0mg immediate release hydrocortisone regimen which may be regarded as 
sufficient and without cortisol trough levels below a value that would pose a safety 
issue.  
In case of administration of modified release hydrocortisone, a once daily 
administration is generally recommended. On the background of the rapid metabolic 
inactivation of cortisol due to increased CYP3A4 activity by mitotane, we assumed 
that a once daily regime might not be sufficient to secure sufficient glucocorticoid 
coverage over the whole day and decided to test a twice daily regimen. However, 
considering our measurements we believe that even a 40mg-20mg-0mg modified 
release hydrocortisone regimen did not provide sufficient free cortisol levels in 
mitotane treated ACC patients. 
Salivary cortisol is regarded as CBG-independent measurement reflecting the free 
serum cortisol. Therefore. it is thought to be a good tool to monitor glucocorticoid 
replacement therapy in ACC patients on mitotane. Our results show massively 
increased salivary cortisol levels with a 40mg-20mg-0 hydrocortisone replacement 
therapy in ACC patients on mitotane. A recent study showed that the ECLIA 
immunoassay possesses a quite large cross-reactivity with endogenous cortisol 
precursors and metabolites, especially with 6β-hydroxycortisol (148% cross 
reactivity) 27, the main cortisol metabolite in mitotane treated patients. Therefore, we 
believe that our salivary results are influenced and overestimated by this cross-
reactivity. This is endorsed by another study showing a significant difference in 
salivary cortisol levels measured with the ECLIA method and LC-MS/MS 28. 
Therefore we suggest that salivary cortisol levels should be measured only with LC-
MS/MS in mitotane treated ACC patients. 
It must be taken into account that both replacement regimes were tested only for one 
day, and we do not have data on longer treatment periods with modified release 
hydrocortisone in mitotane-treated ACC patients. However, it would be interesting to 
further investigate patient acceptance and quality of life in mitotane treated ACC 
patients depending on the form of hydrocortisone replacement therapy. In addition, a 
longer duration of observation would have provided information on the impact of 
potential gastrointestinal effects of mitotane on hydrocortisone kinetics. Longer study 
durations must also include safety aspects such as the frequency of adrenal crisis in 
those patients. The relevance of the lacking morning cortisol peak and the low free 
cortisol levels during the day in ACC patients treated with modified release 
hydrocortisone further remains to be clarified.  
In conclusion, here we show that immediate release but not modified release 
hydrocortisone at a dose of 60mg per day result in sufficient glucocorticoid coverage 
in patients with ACC under mitotane treatment. Glucocorticoid exposure in mitotane-
treated patients receiving modified release hydrocortisone appears to be 
considerably lower compared to the same dose of immediate release hydrocortisone, 
suggesting that the use of equivalent doses of modified release hydrocortisone 
preparation should be avoided in patients on mitotane treatment. 
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Table 1: Patients´ characteristics Median (Range). BMI, body mass index; ACC, 
adrenocortical cancer; SAI, secondary adrenal insufficiency. na = not available 
 
Characteristics ACC patients SAI patients Healthy 
controls 
Male/female 6/3 10/0 10/0 
Age (years) 54 (27-75) 48 (26-71) 45 (27-67) 
Time since diagnosis 
(months) 
44 (6-192) na (36-216) - 
BMI (kg/m2) 24.0 (17.2-33.3) 28.4 (25.4-40.1) 28.3 (25.3-38.5) 
Duration of mitotane 
treatment (months) 
34 (6-87) - - 
Daily mitotane dose (mg) 1500 (0-2500) - - 
 
 
Table 2: 24-hour urine analysis by gas chromatography/mass spectrometry in 9 
adrenocortical cancer (ACC) patients on mitotane, 10 male patients with secondary 
adrenal insufficiency (SAI) on different hydrocortisone (HC) dose regimen, and 10 
healthy male subjects. F = cortisol; THF = tetrahydro-cortisol. Means ± SD.  
 
 6β-OH-F/F ratio 
(CYP3A4 activity ) 
5αTHF/THF ratio  





on 40-20mg HC 
and mitotane 
22.6 ± 4.1 0.05 ± 0.02 27634 ± 6940 
SAI patients on 
20-10mg HC 
2.0 ± 0.2 1.9 ± 0.4 21474 ± 4843 
SAI patients on 
10-10mg HC 
1.9 ± 0.2 1.9 ± 1.1 13502 ± 2979 
SAI patients on 
10-5mg HC 
1.8 ± 0.8 1.9 ± 0.7 11891 ± 3053 
Healthy 
controls 
2.3 ± 0.5 1.1 ± 0.4 14651 ± 7648 
 
 
Figure 1: Serum-Cortisol in nine ACC patients on mitotane receiving 40mg (8.00) 
and 20mg (12.00) of a) immediate release hydrocortisone or b) modified release 
hydrocortisone. Black line = median. Black arrow = time of tablet intake. To convert to 
conventional units, divide cortisol by 27.59 (µg/dl). 
 
Figure 2: Calculated free serum cortisol (nmol/l) in nine ACC patients on mitotane 
receiving 40mg (8.00) and 20mg (12.00) of a) immediate release hydrocortisone or b) 
modified release hydrocortisone. Black line = median. Black arrow = time of tablet 
intake. To convert to conventional units, divide cortisol by 27.59 (µg/dl). 
 
Figure 3: Mean calculated free serum cortisol (nmol/l) in a) nine ACC patients on 
mitotane receiving 40mg (8.00) and 20mg (12.00) of immediate release 
hydrocortisone (blue line) or modified release hydrocortisone (red line), and b) in ten 
male patients with secondary adrenal insufficiency on 20mg-10mg-0 (blue line), 
10mg-10mg-0 (red line) or 10mg-5mg-0 (green line) immediate release 
hydrocortisone dose regimen and in ten healthy male subjects (pink line). Black 
arrow = time of tablet intake (not valid for healthy subjects). Mean ± SEM. To convert 
to conventional units, divide cortisol by 27.59 (µg/dl). 
 
Figure 4: Mean salivary cortisol (nmol/l) in nine ACC patients on mitotane receiving 
40mg (8.00) and 20mg (12.00) of immediate release hydrocortisone (blue line) or 
modified release hydrocortisone (red line). Black arrow = time of tablet intake. Mean 
± SEM. To convert to conventional units, divide cortisol by 27.59 (µg/dl). The range of 
normal salivary cortisol morning levels (1.3-25.7nmol/l) is shown as grey area. 
 
